4D Molecular Therapeutics (4D Molecular Therapeutics) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is 4D Molecular Therapeutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of 4D Molecular Therapeutics is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of 4D Molecular Therapeutics's Risk Assessment

For the Biotechnology subindustry, 4D Molecular Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4D Molecular Therapeutics's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where 4D Molecular Therapeutics's Risk Assessment falls into.

4D Molecular Therapeutics (NAS:FDMT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

4D Molecular Therapeutics Risk Assessment Related Terms

Thank you for viewing the detailed overview of 4D Molecular Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

4D Molecular Therapeutics (4D Molecular Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4D Molecular Therapeutics Inc (NAS:FDMT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608

Website

https://www.4dmoleculartherapeutics.com

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

Executives

David Kirn	director, officer: Chief Executive Officer	C/O 4D MOLECULAR THERAPEUTICS INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Uneek Mehra	officer: See Remarks	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Jacob Chacko	director	C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Scott Bizily	officer: Chief Legal and HR Officer	C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Robert Young Kim	officer: Chief Medical Officer	C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Noriyuki Kasahara	director	C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104